Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 15;108(7):1768–1781. doi: 10.3324/haematol.2022.281692

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2023 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 3. — Determination of the predictive value of drug sensitivity testing in different cohorts of patients. (A) The sensitivity of each participant to venetoclax, determined using flow cytometry and conditioned medium and expressed as a drug sensitivity score (DSS). The participants are divided into responders and non-responders. The dashed line at DSS 10.7 represents the best cutoff value. The P value was calculated using a one-tailed Mann-Whitney U test. (B) Receiver operating characteristic (ROC) curve analysis of DSS and clinical response using the Wilson-Brown method. (C) Sensitivity, specificity, positive predictive value and negative predictive value of the test when using the cutoff value of DSS 10.7, illustrated in a confusion matrix. (D) DSS versus clinical response in relapsed/refractory (R/R) or secondary acute myeloid leukemia (sAML). The P value was calculated using a one-tailed Mann-Whitney U test. (E) ROC analysis of R/R or sAML. (F) Predictive value of the test in R/R or sAML. (G) DSS versus clinical response in de novo AML. The P value was calculated using a one-tailed Mann-Whitney U test. (H) ROC analysis of de novo AML. (I) Predictive value of the test in de novo AML. DSS: drug sensitivity score; FC: flow cytometry; CM: conditioned medium; RD: refractory disease; PD: progressive disease; CR: complete remission; CRi: complete remission with incomplete blood recovery; MLFS: morphological leukemia-free state.